- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04586803
Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers
Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers (Single Center, Randomized, Open, 3 Cycles, 6 Sequences)
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Study Type: Interventional Enrollment: Number of Subjects: 24 Type: Anticipated
Allocation : Yes Intervention Model : Single center, randomized, open Intervention Model Description: 3 cycles, 6 sequences Masking: No Masking
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
Opintotyyppi
Ilmoittautuminen (Odotettu)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- 1) Voluntarily sign the informed consent form before the start of the activities related to this trial, and be able to understand the procedures and methods of this trial, and be willing to strictly abide by the clinical trial plan to complete this trial; 2) Aged between 18 and 45 years old (including both ends, whichever is the time of signing the informed consent form), male; 3) Body weight ≥ 50 kg, and body mass index (BMI): 19-26 kg/m2 (both ends included).
Exclusion Criteria:
Subjects will not be allowed to enter this study if they meet any of the following criteria:
1. General situation:
- Have a fertility plan within 3 months after screening to the last medication, or refuse to use medically approved contraceptive methods;
- Drug abusers or drug urine screening positive;
- Smokers (average daily smoking 5 or more) or urine Nicotin positive.
- The average daily alcohol intake during the first month was more than 25 g (for example, 750 mL beer, 250 mL wine or 50 mL low spirits);
- Anyone who had eaten grapefruit or fruit juice products within 2 days before administration, any food or drink containing caffeine (such as coffee, tea, chocolate, cola or other caffeinated carbonated drinks, etc.) and foods or drinks rich in purine food or alcohol.
- The researchers judged that the subjects had medical conditions that affected the absorption, distribution, metabolism and excretion of drugs or reduced compliance.
2. Laboratory tests showed the following conditions:
- Those with sUA > 420 µmol / L during the screening period, or those with a previous history of hyperuricemia and / or gout;
- Those with estimated glomerular filtration rate (eGFR) < 90 during the screening period;
- Those with urolithiasis indicated or suspected by B ultrasound during the screening period;
- Those who were positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody or syphilis antibody within one month or during the screening period.
3. There is any history of any of the following or concomitant diseases:
- Any clinical history of serious illness or disease or condition that the researchers believe may affect the results of the trial, including, but not limited to, a history of circulatory, endocrine, nervous, digestive, urinary or hematological, immune, mental and metabolic diseases.
- People with allergies, including those who are explicitly allergic to research drugs or any ingredient in research drugs, are allergic to any food ingredient or have special requirements for diet, and are unable to follow a uniform diet;
- Screening those who have undergone any operation within the first 3 months, or who have not recovered after the operation, or who may have a plan for operation or hospitalization during the trial;
- Those who donated blood (or lost blood) within the first 3 months and donated blood (or lost blood) more than 400 mL, or received blood transfusion.
4. Use any of the following drugs or participate in clinical trials:
- Screen people who have participated in clinical trials of any drug or medical device within the previous 3 months;
- Take any prescription drug, over-the-counter medicine, Chinese herbal medicine or dietary supplement within 2 weeks before the screening period.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Perustiede
- Jako: Satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: A
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
|
Kokeellinen: B
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
|
Kokeellinen: C
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
|
Kokeellinen: D
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
|
Kokeellinen: E
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
|
Kokeellinen: F
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Cmax
Aikaikkuna: Day1 to Day25
|
Peak plasma concentration
|
Day1 to Day25
|
|
AUC0-t
Aikaikkuna: Day1 to Day25
|
Area under the curve from the time of dosing.
Dosing time to the last measurable (positive) concentration.
|
Day1 to Day25
|
|
AUC0-inf(if available)
Aikaikkuna: Day1 to Day25
|
Area under the curve from time 0 to infinity
|
Day1 to Day25
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Tmax
Aikaikkuna: Day1 to Day25
|
Time of maximum observed concentration
|
Day1 to Day25
|
|
t1/2
Aikaikkuna: Day1 to Day25
|
Half time
|
Day1 to Day25
|
|
CL/F
Aikaikkuna: Day1 to Day25
|
apparent clearance
|
Day1 to Day25
|
|
Vz/F
Aikaikkuna: Day1 to Day25
|
apparent volume of distribution
|
Day1 to Day25
|
|
PD
Aikaikkuna: Day1 to Day25
|
concentration of serum urine acid
|
Day1 to Day25
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Zourong Ruan, PhD, The Second Affiliated Hospital of Medical College of Zhejiang University
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Odotettu)
Ensisijainen valmistuminen (Odotettu)
Opintojen valmistuminen (Odotettu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- SHR4640-Ⅰ-109
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset SHR4640
-
Atridia Pty Ltd.Valmis
-
Jiangsu HengRui Medicine Co., Ltd.Valmis
-
Jiangsu HengRui Medicine Co., Ltd.Valmis
-
Jiangsu HengRui Medicine Co., Ltd.Tuntematon
-
Jiangsu HengRui Medicine Co., Ltd.ValmisTerveet aikuiset miespuoliset vapaaehtoisetKiina
-
Jiangsu HengRui Medicine Co., Ltd.Valmis
-
Jiangsu HengRui Medicine Co., Ltd.RekrytointiPrimaarinen kihti ja hyperurikemiaKiina
-
Jiangsu HengRui Medicine Co., Ltd.Aktiivinen, ei rekrytointiMaksan vajaatoimintaKiina
-
Atridia Pty Ltd.ValmisHyperurikemia | KihtiAustralia
-
Jiangsu HengRui Medicine Co., Ltd.Tuntematon